Who is sponsoring NCT00608699?

NCT00608699 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT00608699?

Interventions in NCT00608699: GSK256073A tablets + IR niacin tablets.

What condition does NCT00608699 study?

NCT00608699 studies Healthy Subjects, Dyslipidaemias.

Is NCT00608699 still recruiting?

NCT00608699 is currently completed. Last updated 26 April 2012.

Last reviewed 2012-04-26 · How we verify

NCT00608699

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Ability of the HM74A Agonist GSK256073A to Block Niacin-induced Flushing in Healthy Adult Subjects

Completed Phase 1 Last updated 26 April 2012

What this trial tests

Phase 1 trial testing GSK256073A tablets + IR niacin tablets in Healthy Subjects in 24 participants. Completed in 1 April 2008.

Timeline

1 December 2007

Primary endpoint
1 April 2008

1 April 2008

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	single
Primary purpose	diagnostic
Enrollment	24
Start date	1 December 2007
Primary completion	1 April 2008
Estimated completion	1 April 2008
Sites	1 location across United States

Drugs / interventions tested

GSK256073A tablets + IR niacin tablets — full drug profile →

Conditions studied

Healthy Subjects — all drugs for Healthy Subjects →
Dyslipidaemias — all drugs for Dyslipidaemias →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 18 to 55, male only, with Healthy Subjects or Dyslipidaemias. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Intensity of reported flushing - visual analogue scale; self reported assessment of flushing
Time frame: up to 8 hours post dose
Safety and tolerability of GSK256073A and immediate release niacin
Time frame: up to 36 hours post dose

Sponsor's own description

To test the ability of GSK256073 to block niacin-induced flushing when GSK256073 and niacin are co-administered as single doses to HVTs.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

NAD<sup>+</sup> metabolism: pathophysiologic mechanisms and therapeutic potential.
Xie N, Zhang L, Gao W, Huang C, et al · · 2020 · cited 744× · PMID 33028824 · DOI 10.1038/s41392-020-00311-7
GPCRs involved in metabolic diseases: pharmacotherapeutic development updates.
Jin C, Chen H, Xie L, Zhou Y, et al · · 2024 · cited 25× · PMID 38326623 · DOI 10.1038/s41401-023-01215-2

Verify or expand the search:

Other recruiting trials for Healthy Subjects

Currently open trials in the same condition.

NCT07222020 — Phase 1 Study of Intravaginal KB15A · Phase 1 · recruiting
NCT07350538 — The Critical Link Between Gut Microbiome Dysfunction, Cravings and Relapse: RECLAIM-GUT TRIAL · NA · active not recruiting
NCT07304791 — This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and P · Phase 1 · recruiting
NCT07059858 — Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities · recruiting
NCT07331389 — A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin · Phase 1 · recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00608699 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 26 April 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00608699.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing